A major milestone was achieved with the approval of Patisiran (ONPATTRO®) in 2018, the first FDA-approved liver-targeted siRNA therapeutic to treat hereditary transthyretin (TTR) amyloidosis. This evidence concerns the gene TTR and amyloidosis.